Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10208572rdf:typepubmed:Citationlld:pubmed
pubmed-article:10208572lifeskim:mentionsumls-concept:C0039485lld:lifeskim
pubmed-article:10208572lifeskim:mentionsumls-concept:C0036341lld:lifeskim
pubmed-article:10208572lifeskim:mentionsumls-concept:C0080093lld:lifeskim
pubmed-article:10208572pubmed:issue3lld:pubmed
pubmed-article:10208572pubmed:dateCreated1999-6-10lld:pubmed
pubmed-article:10208572pubmed:abstractTextSaturation analyses of [3H]L-689,560, [3H]CGP 39653 and NMDA-specific [3H]ifenprodil binding revealed an equivalent increase (0.7 pmol/mg) in the number of [3H]L-689,560 and [3H]ifenprodil binding sites in superior temporal cortex (BA22) from drug-treated chronic schizophrenic patients and control subjects. No differences were observed between control and schizophrenic subjects for [3H]CGP 39653 binding in BA22, or for any of the radioligands binding to pre-motor cortex (BA6). Since [3H]L-689,560, [3H]CGP 39653 and [3H]ifenprodil label the glycine, glutamate and ifenprodil sites of the NMDA receptor complex, which are associated with NR1, NR1/NR2A and NR1/NR2B subunits respectively, our findings suggest that NR2B-containing receptors are selectively up-regulated in superior temporal cortex in schizophrenia.lld:pubmed
pubmed-article:10208572pubmed:languageenglld:pubmed
pubmed-article:10208572pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10208572pubmed:citationSubsetIMlld:pubmed
pubmed-article:10208572pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10208572pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10208572pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10208572pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10208572pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10208572pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10208572pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10208572pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10208572pubmed:statusMEDLINElld:pubmed
pubmed-article:10208572pubmed:monthFeblld:pubmed
pubmed-article:10208572pubmed:issn0959-4965lld:pubmed
pubmed-article:10208572pubmed:authorpubmed-author:DeakinJ FJFlld:pubmed
pubmed-article:10208572pubmed:authorpubmed-author:SlaterPPlld:pubmed
pubmed-article:10208572pubmed:authorpubmed-author:HutsonP HPHlld:pubmed
pubmed-article:10208572pubmed:authorpubmed-author:GrimwoodSSlld:pubmed
pubmed-article:10208572pubmed:issnTypePrintlld:pubmed
pubmed-article:10208572pubmed:day25lld:pubmed
pubmed-article:10208572pubmed:volume10lld:pubmed
pubmed-article:10208572pubmed:ownerNLMlld:pubmed
pubmed-article:10208572pubmed:authorsCompleteYlld:pubmed
pubmed-article:10208572pubmed:pagination461-5lld:pubmed
pubmed-article:10208572pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:10208572pubmed:meshHeadingpubmed-meshheading:10208572...lld:pubmed
pubmed-article:10208572pubmed:meshHeadingpubmed-meshheading:10208572...lld:pubmed
pubmed-article:10208572pubmed:meshHeadingpubmed-meshheading:10208572...lld:pubmed
pubmed-article:10208572pubmed:meshHeadingpubmed-meshheading:10208572...lld:pubmed
pubmed-article:10208572pubmed:meshHeadingpubmed-meshheading:10208572...lld:pubmed
pubmed-article:10208572pubmed:meshHeadingpubmed-meshheading:10208572...lld:pubmed
pubmed-article:10208572pubmed:meshHeadingpubmed-meshheading:10208572...lld:pubmed
pubmed-article:10208572pubmed:meshHeadingpubmed-meshheading:10208572...lld:pubmed
pubmed-article:10208572pubmed:meshHeadingpubmed-meshheading:10208572...lld:pubmed
pubmed-article:10208572pubmed:meshHeadingpubmed-meshheading:10208572...lld:pubmed
pubmed-article:10208572pubmed:meshHeadingpubmed-meshheading:10208572...lld:pubmed
pubmed-article:10208572pubmed:meshHeadingpubmed-meshheading:10208572...lld:pubmed
pubmed-article:10208572pubmed:meshHeadingpubmed-meshheading:10208572...lld:pubmed
pubmed-article:10208572pubmed:year1999lld:pubmed
pubmed-article:10208572pubmed:articleTitleNR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia.lld:pubmed
pubmed-article:10208572pubmed:affiliationMerck Sharp & Dohme Neuroscience Research Laboratories, Harlow, Essex, UK.lld:pubmed
pubmed-article:10208572pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10208572lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10208572lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10208572lld:pubmed